Latest 10-Q quarterly reports

CIMG Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing significant revenue growth driven by new product series, but also highlighting substantial net losses and ongoing concerns about its ability to continue as a going concern.

Exagen Inc. reported an 11.7% increase in revenue for the first quarter of 2026, driven by biomarker enhancements and a growing average selling price.

Circle Internet Group reports a 20% increase in total revenue to $694 million for Q1 2026, driven by reserve income and other revenue growth, while net income from continuing operations decreased by 15% to $55 million.

Forte Biosciences reported a net loss of $22.1 million for Q1 2026, with research and development expenses significantly increasing, while cash reserves remain substantial following a recent public offering.

MAIA Biotechnology, Inc. reported its first quarter 2026 financial results, highlighting increased operating expenses and significant cash inflow from financing activities, while advancing its lead oncology drug candidate, ateganosine.

MoonLake Immunotherapeutics reports increased R&D spending and net loss in Q1 2026, driven by clinical trial progression and stock option expense, while maintaining sufficient capital through 2027.

American Battery Technology Company reported a significant increase in revenue for the third quarter of fiscal year 2026, driven by higher production volumes and market prices, while also addressing material weaknesses in internal controls.

Envoy Medical, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, progress on its Acclaim CI product, and ongoing operational challenges.

Global Business Travel Group, Inc. reported a 35% increase in revenue for Q1 2026, reaching $840 million, but net income decreased to $54 million from $75 million in the prior year.

Priority Technology Holdings reported an 11.1% increase in revenue for the first quarter of 2026, reaching $249.6 million, driven by growth across its Merchant Solutions, Payables, and Treasury Solutions segments.

Heron Therapeutics reported a net loss of $8.1 million for Q1 2026, with net product sales decreasing to $34.7 million compared to $38.9 million in the prior year period.

Intellia Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its CRISPR-based gene editing programs for HAE and ATTR amyloidosis, alongside a net loss of $96.2 million.

Abacus Global Management reports a significant increase in Q1 2026 revenue, driven by strong performance in its Life Solutions segment, despite a rise in operating expenses.

Cronos Group Inc. announced its first quarter 2026 financial results, showing a significant increase in net revenue and a return to profitability.

Dyne Therapeutics reported a wider net loss for Q1 2026, driven by increased research and development expenses, particularly for its z-rostudirsen program, while general and administrative costs also rose.

Apogee Therapeutics, Inc. reported a net loss of $74.1 million for the first quarter of 2026, with significant investments in research and development for its inflammatory and immunology programs.

FS KKR Capital Corp. reported its first quarter 2026 financial results, showing a decrease in net investment income and a net loss for the period.

Lexeo Therapeutics reported its first-quarter 2026 financial results, highlighting progress in its gene therapy pipeline for cardiovascular diseases and a strong cash position.

Keel Infrastructure Corp. (formerly Bitfarms Ltd.) filed its Q1 2026 10-Q, detailing a significant net loss and a strategic pivot towards High-Performance Computing (HPC) and Artificial Intelligence (AI) infrastructure.

Liquidia Corporation announced a substantial increase in revenue for the first quarter of 2026, driven by strong product sales of YUTREPIA.

Perpetua Resources reports significant progress in Q1 2026, with key advancements in project financing, including U.S. EXIM loan progress, and increased exploration and pre-development expenditures.

Village Farms International Inc. announced a significant increase in Q1 2026 revenue, driven by a surge in international cannabis exports and improved gross margins.

ARKO Petroleum Corp. reported a significant increase in net income for the first quarter of 2026, driven by higher fuel revenues and strategic site conversions.

Emerald Holding reported a 5.2% increase in Q1 2026 revenue to $155.4 million, but net income fell to $7.2 million from $15.3 million in the prior year.

Olaplex Holdings, Inc. reported a net loss for Q1 2026, despite a 2.5% increase in net sales, as the company navigates a proposed acquisition by Henkel.

Certara, Inc. reported Q1 2026 results with a net loss, while also announcing the divestiture of its global medical writing business.

Elme Communities is proceeding with its plan of liquidation, reporting the sale of multiple properties and providing an updated estimate for remaining liquidating distributions.

eXp World Holdings reported a 5% increase in Q1 2026 revenue to $1.006 billion, but a net loss of $5.1 million, widening from the previous year.

Babcock & Wilcox Enterprises, Inc. reported a significant increase in revenue for the first quarter of 2026, driven by large project volume, but also experienced a substantial non-cash charge related to customer warrants.

Townsquare Media reported a 1.9% decrease in net revenue for Q1 2026 compared to the prior year, primarily due to declines in Broadcast Advertising and Subscription Digital Marketing Solutions, alongside an $8.6 million impairment charge on FCC licenses.